Search
You have executed a tag search on The Deal Pipeline. Below, you will find a comprehensive list of stories tagged "Novartis AG."
12 result(s) displayed (1 - 12 of 15)
Deal represents a 34% premium to Dublin target's share price prior to May 9 disclosure of merger discussions. Continue reading
Posted on May 20, 2013 9:28 AM
The transaction, worth up to $1.85 billion, is the third-largest acquisition of an Indian pharmaceuticals company to date. Continue reading
Posted on February 28, 2013 8:12 AM
In a seldom-seen move, the Swiss pharma giant, the California venture capital firm and Inception Sciences will form an entity to create drugs to treat sensorineural hearing loss which Roche will then have an option to buy. Continue reading
Posted on October 15, 2012 10:41 AM
The two German companies will collaborate on the development of three compounds for the female health malady over a five-year period under a deal that could be worth as much as $750 million. Continue reading
Posted on October 1, 2012 4:04 PM
The buyout firms sell Fougera to Novartis for $1.53 billion after spinning the U.S. business off from Nycomed when they sold the larger company to Takeda last year. Continue reading
Posted on May 3, 2012 2:11 PM
Nestlé triumphs over Danone with a bid valuing the business at 19.8 times forecast Ebitda Continue reading
Posted on April 23, 2012 10:28 AM
The draft outlines the approval process for biosimilars Continue reading
Posted on February 13, 2012 9:16 AM
China is emerging as a major merger control jurisdiction that can reach out to review, delay and in the worst case block important deals Continue reading
Posted on December 19, 2011 3:21 PM
In 2011, risk sharing returned to dealmaking in the sector as overconfidence left the market. Continue reading
Posted on December 9, 2011 12:00 PM
The generic drugmaker will pay Kowa $150 million as part of a plan to establish itself as a market leader in Japan. Continue reading
Posted on September 26, 2011 3:13 PM
With 16 Big Pharma partnerships worth more than $3.3 billion in potential milestones and royalty payments, Array BioPharma Inc. is poised to turn from a net loss clinical-stage biopharma to a revenue-growing drug seller.Those reasons could also make it an... Continue reading
Posted on September 20, 2011 9:28 AM
Article One Partners enlists any and all sleuths to probe for weaknesses in patents. Continue reading
Posted on February 5, 2010 11:58 AM
Movable Type search results powered by Fast Search
Ken deRegt will retire as head of fixed income at Morgan Stanley and be replaced by Michael Heaney and Robert Rooney. For other updates launch today's Movers & shakers slideshow.
Apax Partners offers $1.1 billion for Rue21, the same teenage fashion chain it took public in 2009. More video
